|
Gene: TRIM16L |
Gene summary for TRIM16L |
Gene summary. |
Gene information | Species | Human | Gene symbol | TRIM16L | Gene ID | 147166 |
Gene name | tripartite motif containing 16 like | |
Gene Alias | TRIM70 | |
Cytomap | 17p11.2 | |
Gene Type | pseudo | GO ID | GO:0005575 | UniProtAcc | Q309B1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
147166 | TRIM16L | P27T-E | Human | Esophagus | ESCC | 4.40e-12 | 3.21e-01 | 0.1055 |
147166 | TRIM16L | P28T-E | Human | Esophagus | ESCC | 9.56e-15 | 3.32e-01 | 0.1149 |
147166 | TRIM16L | P30T-E | Human | Esophagus | ESCC | 6.33e-31 | 1.37e+00 | 0.137 |
147166 | TRIM16L | P31T-E | Human | Esophagus | ESCC | 1.13e-17 | 4.35e-01 | 0.1251 |
147166 | TRIM16L | P32T-E | Human | Esophagus | ESCC | 4.59e-57 | 1.71e+00 | 0.1666 |
147166 | TRIM16L | P36T-E | Human | Esophagus | ESCC | 6.07e-06 | 1.43e-01 | 0.1187 |
147166 | TRIM16L | P37T-E | Human | Esophagus | ESCC | 3.86e-06 | 1.49e-01 | 0.1371 |
147166 | TRIM16L | P39T-E | Human | Esophagus | ESCC | 1.74e-21 | 5.47e-01 | 0.0894 |
147166 | TRIM16L | P40T-E | Human | Esophagus | ESCC | 5.05e-03 | 2.07e-01 | 0.109 |
147166 | TRIM16L | P42T-E | Human | Esophagus | ESCC | 2.32e-15 | 6.28e-01 | 0.1175 |
147166 | TRIM16L | P47T-E | Human | Esophagus | ESCC | 1.47e-18 | 4.32e-01 | 0.1067 |
147166 | TRIM16L | P48T-E | Human | Esophagus | ESCC | 9.04e-09 | 2.82e-01 | 0.0959 |
147166 | TRIM16L | P49T-E | Human | Esophagus | ESCC | 2.50e-19 | 2.60e+00 | 0.1768 |
147166 | TRIM16L | P52T-E | Human | Esophagus | ESCC | 8.42e-17 | 7.38e-01 | 0.1555 |
147166 | TRIM16L | P54T-E | Human | Esophagus | ESCC | 1.85e-03 | 7.92e-02 | 0.0975 |
147166 | TRIM16L | P61T-E | Human | Esophagus | ESCC | 7.60e-04 | 1.51e-01 | 0.099 |
147166 | TRIM16L | P62T-E | Human | Esophagus | ESCC | 1.73e-09 | 1.97e-01 | 0.1302 |
147166 | TRIM16L | P65T-E | Human | Esophagus | ESCC | 8.40e-07 | 8.96e-02 | 0.0978 |
147166 | TRIM16L | P74T-E | Human | Esophagus | ESCC | 6.00e-04 | 2.42e-01 | 0.1479 |
147166 | TRIM16L | P75T-E | Human | Esophagus | ESCC | 2.72e-06 | 8.99e-02 | 0.1125 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIM16L | SNV | Missense_Mutation | c.415N>C | p.Tyr139His | p.Y139H | Q309B1 | protein_coding | tolerated(0.74) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TRIM16L | SNV | Missense_Mutation | rs752949316 | c.530G>A | p.Arg177His | p.R177H | Q309B1 | protein_coding | tolerated(0.13) | benign(0.299) | TCGA-EX-A69M-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
TRIM16L | SNV | Missense_Mutation | c.828C>G | p.Phe276Leu | p.F276L | Q309B1 | protein_coding | tolerated(0.08) | benign(0.334) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
TRIM16L | SNV | Missense_Mutation | c.44C>T | p.Ala15Val | p.A15V | Q309B1 | protein_coding | tolerated(0.12) | benign(0.022) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
TRIM16L | SNV | Missense_Mutation | rs368943120 | c.409N>T | p.Arg137Cys | p.R137C | Q309B1 | protein_coding | tolerated(0.11) | benign(0.431) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TRIM16L | SNV | Missense_Mutation | rs749951466 | c.977N>T | p.Ala326Val | p.A326V | Q309B1 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIM16L | SNV | Missense_Mutation | rs552209237 | c.976N>A | p.Ala326Thr | p.A326T | Q309B1 | protein_coding | tolerated(0.52) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRIM16L | SNV | Missense_Mutation | novel | c.654G>T | p.Glu218Asp | p.E218D | Q309B1 | protein_coding | tolerated(0.31) | benign(0.058) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
TRIM16L | SNV | Missense_Mutation | novel | c.223A>G | p.Thr75Ala | p.T75A | Q309B1 | protein_coding | tolerated(0.9) | benign(0.02) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRIM16L | SNV | Missense_Mutation | rs757995912 | c.283N>T | p.Arg95Cys | p.R95C | Q309B1 | protein_coding | deleterious(0.02) | benign(0.005) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |